Jodie Pope Morrison
CIK 1618247 · CEO · last filed 2026-10-14
Jodie Pope Morrison is a CEO who has filed 34 SEC Form 4 insider transactions across 7 companies since 2014. The most recent filing shows the insider sold $26.8K of QTTB on Oct 14, 2026. Across all open-market trades the lifetime net is −$723.6K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.9M across reported positions. 1 Form 144 notice of planned sales is also on file; the latest, for QTTB on Dec 2, 2025, lists the filer as an officer and director.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TKAI price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
830 WINTER STREET
WALTHAM, MA 02451
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| QTTB | CEO | 340,038 | $8.48 | $2.88M | -$331.3K | 9 | 2026-10-14 |
| Verve Therapeutics, Inc. (VERV) Delisted | Director | — | $11.13 | — | $0 | 3 | 2025-07-28 |
| Rein Therapeutics, Inc. (ALRN) Delisted | Director | — | $2.11 | — | $0 | 6 | 2022-06-17 |
| AKBA | Director | 58,619 | $0.42 | $24.5K | $0 | 2 | 2019-06-10 |
| KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Interim CEO | 0 | — | — | $0 | 5 | 2018-12-13 |
| Eledon Pharmaceuticals, Inc. (NVUS) Delisted | Director | — | — | — | $0 | 1 | 2017-07-05 |
| Eledon Pharmaceuticals, Inc. (TKAI) Delisted | President and CEO | 6,396 | — | — | -$392.4K | 7 | 2016-01-08 |
Recent Filings
34 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-14 | QTTB | Sell (S) | −3,221 | -$26.8K | EDGAR |
| 2026-08-27 | QTTB | Sell (S) | −9,845 | -$163.0K | EDGAR |
| 2026-07-20 | QTTB | Grant (A) | +132,000 | $0 | EDGAR |
| 2026-03-20 | QTTB | Grant (A) | +132,000 | $0 | EDGAR |
| 2026-02-27 | QTTB | Sell (S) | −9,896 | -$44.7K | EDGAR |
| 2025-12-04 | QTTB | Sell (S) | −22,506 | -$77.9K | EDGAR |
| 2025-12-02 | QTTB | Notice (144) Officer, Director · Planned Dec 2, 2025 Sold: Form 4 filed Dec 4, 2025 |
−22,506 | -$77.9K | EDGAR |
| 2025-08-28 | QTTB | Sell (S) | −10,494 | -$18.9K | EDGAR |
| 2025-07-28 | Verve Therapeutics, Inc. (VERV) Delisted | Disp (D) | — | $0 | EDGAR |
| 2025-06-06 | Verve Therapeutics, Inc. (VERV) Delisted | Grant (A) | — | $0 | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).